Differential modulation of leukotriene B4 synthesis and degradation in human bronchoalveolar lavage cells by lipopolysaccharide and tobacco smoke

Cancer Prevention Research

Volumn 1, Issue 4, 2008, Pages 266-274

  Mao, Jenny T ^a   Tashkin, Donald P ^a   Tsu, I Hsien ^a   Serio, Kenneth J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS GREEN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CYTOCHROME P450; LEUKOTRIENE B4; LEUKOTRIENE B4 20 HYDROXYLASE; LEUKOTRIENE B4 20-HYDROXYLASE; LIPOPOLYSACCHARIDE; MESSENGER RNA;

AGED; ARTICLE; CARCINOMA; CELL CULTURE; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG; LUNG LAVAGE; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; SMOKING;

AGED; AGED, 80 AND OVER; ARACHIDONATE 5-LIPOXYGENASE; BRONCHOALVEOLAR LAVAGE FLUID; CARCINOMA; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LEUKOTRIENE B4; LIPOPOLYSACCHARIDES; LUNG; LUNG NEOPLASMS; MIDDLE AGED; RNA, MESSENGER; SMOKING;

EID: 61549113152     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0001     Document Type: Article

References (30)

1. Wallace JM. Nutritional and botanical modulation of the inflammatory cascade-eicosanoids, cyclooxygenases, and lipoxygenases-as an adjunct in cancer therapy. Integr Cancer Ther 2002;1:7-37, discussion 37.
2. Dixon RA, Diehl RE, Opas E, et al. Requirement of a 5-lipoxygenase- activating protein for leukotriene synthesis. Nature 1990;343:282-4.
3. 4 in human polymorphonuclear leukocytes. J Biol Chem1984;259:10181-7.
4. 4 ω-hydroxylase (CYP4F3) gene: molecular cloning and chromosomal localization. DNA Cell Biol 1998;17:221-30.
5. 4 in the human subject. J Biol Chem 2003;278: 24449-60. Epub 2003 Apr 22.
6. 4, peptide leukotrienes, and interleukin- 8 plasma concentrations in patients at risk of acute respiratory distress syndrome and with acute respiratory distress syndrome: mortality prognostic study. Crit Care Med 2000;28:57-62.
7. Avis IM, Jett M, Boyle T, et al. Growth control of lung cancer by interruption of 5-lipoxygenasemediated growth factor signaling. J Clin Invest 1996;97:806-13.
8. Kilfeather S. 5-Lipoxygenase inhibitors for the treatment of COPD. Chest 2002;121:197S-200S.
9. 4 and leukotriene E4 in bronchoalveolar lavage fluid frompa tients with scleroderma lung disease. Arthritis Rheum 2003; 48:1639-46.
10. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990;323: 645-55.
11. Nicosia S, Capra V, Rovati GE. Leukotrienes as mediators of asthma. Pulm Pharmacol Ther 2001; 14:3-19.
12. Parnes SM. The role of leukotriene inhibitors in allergic rhinitis and paranasal sinusitis. Expert Opin Pharmacother 2002;3:33-8.
13. 4 on bovine aortic endothelial cell proliferation in vitro. Prostaglandins 1987;33:531-8.
14. Avis I, Hong SH, Martinez A, et al. Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J 2001;15:2007-9.
15. Ferry DR, Deakin M, Baddeley J, et al. A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic end points. Ann Oncol 2000;11:1165-70.
16. Ghosh J, Myers CE. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem Biophys Res Commun 1997; 235:418-23.
17. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 2001;91:737-43.
18. Kargman S, Vickers PJ, Evans JF. A23187- induced translocation of 5-lipoxygenase in osteosarcoma cells. J Cell Biol 1992;119:1701-9.
19. 2 synthase. Adv Exp Med Biol 2002;507: 457-62.
20. 2 and interleukin- 10 production in alveolar macrophages fromactive smokers. Clin Cancer Res 2003;9: 5835-41.
21. AderemA A, Cohen DS, Wright SD, Cohn ZA. Bacterial lipopolysaccharides prime macrophages for enhanced release of arachidonic acid metabolites. J Exp Med 1986;164:165-79.
22. Coffey MJ, Phare SM, Peters-Golden M. Prolonged exposure to lipopolysaccharide inhibits macrophage 5-lipoxygenase metabolism via induction of nitric oxide synthesis. J Immunol 2000;165: 3592-8.
23. 4 synthase gene in the monocyte-like cell line, THP-1. J Immunol 2003;170:2121-8.
24. Mao JT, Tsu IH, Dubinett SM, et al. Modulation of pulmonary leukotriene B4 production by cyclooxygenase- 2 inhibitors and lipopolysaccharide. Clin Cancer Res 2004;10:6872-8.
25. Sarafian TA,Magallanes JAM, ShauHY, Tashkin D, Roth MD. Oxidative stress produced by Marijuana smoke-an adverse effect enhanced by cannabinoids. AmJ Respir Cell Mol Biol 1999;20:1286-93.
26. Brock TG, McNish RW, Mancuso P, Coffey MJ, Peters-Golden M. Prolonged lipopolysaccharide inhibits leukotriene synthesis in peritoneal macrophages: mediation by nitric oxide and prostaglandins. Prostaglandins Other Lipid Mediat 2003;71: 131-45.
27. Fan H, Cook JA. Molecular mechanisms of endotoxin tolerance. J Endotoxin Res 2004;10:71-84.
28. Lin SM, Frevert CW, Kajikawa O, et al. Differential regulation of membrane CD14 expression and endotoxin- tolerance in alveolar macrophages. Am J Respir Cell Mol Biol 2004;31:162-70.
29. Murad F. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med 2006; 355:2003-11.
30. Coffey RG, Diaz S, Coffey CS. Effects of inhibition of lipoxygenase and guanylate cyclase on human neutrophil responses to formyl peptide and granulocyte-macrophage colony-stimulating factor. J Leukoc Biol 1993;54:89-96.